Tissue-residing cDCs can be divided into two functionally specialized subsets: conventional type 1 DCs (CD103+ cDC1s), which especially excel at cross-presenting tumor antigens to prime and activate CD8+ T cells, and conventional type 2 DCs (CD11b+cDC2s), which are more adept at driving helper CD4+ T cell responses [16, 17].The presence of mature DCs (CD83 positive DCs) has been reported to be associated with a significantly lower incidence of LNM and improved survival outcomes in a limited cohort of patients with cholangiocarcinoma [18]. Here, CD8A is linked to neoplasm.